Keywords: Roche, Illumina, Hostile tender offer, DNA sequencing, Letters to shareholders

Roche presses on with takeover, despite further rejection by Illumina board

Article | 04 April 2012

Print This

Swiss drug major Roche (ROG: SIX), admitting disappointment that the board of Illumina (Nasdaq: ILMN) has rejected its increased offer, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in